tbuckley/cabot-search huggingface dataset:
Combination Therapy with Lumacaftor–Ivacaftor in Cystic Fibrosis. Keeping It Real
Authors: Marc A. Sala, Manu Jain
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

Combination Therapy with Lumacaftor-Ivacaftor in Cystic Fibrosis Keeping It RealIvacaftor was approved by the U.S. Food and Drug Administration in 2012 for patients with cystic fibrosis (CF) carrying the G551D mutation and represented the first treatment that targeted mutant CFTR (cystic fibrosis transmembrane regulator) protein, the underlying cause of CF.Subsequently, several real-world studies have expanded our understanding of ivacaftor's effects on longterm pulmonary and nonpulmonary outcomes (1-3).Because it is approved for only about 10% of patients with CF, there remained a substantial unmet need.The most common mutation in patients with CF is a phenylalanine deletion at amino acid 508, termed F508del, which results in complex protein abnormalities that require multiple drugs to effect clinically meaningful CFTR restoration.The combination of a CFTR corrector and potentiator, lumacaftor-ivacaftor, was approved in 2015 after two concurrent phase 3 trials that established its efficacy in increasing FEV 1 and reducing pulmonary exacerbations (4).During the phase 3 studies and in subsequent reports, it was noted that the combination (likely resulting from lumacaftor) was associated with significant adverse effects, most notably chest tightness (8.7% vs. 5.9% in placebo) and dyspnea (13.0%vs.7.8%), with an overall discontinuation rate of 4.2% in treated subjects compared with 1.6% in the placebo group.In this issue of the Journal, Burgel and colleagues (pp.188-197) report on the real-world effectiveness and safety of lumacaftorivacaftor in French patients treated for 1 year (5).This is an important follow-up study to the phase 3 trials for a few reasons, two of which are that this study includes patients excluded in the phase 3 trials and that it reports on nonpulmonary outcomes.There are several strengths to the study by Burgel and colleagues.These include the large number of participants (N = 845) from many CF clinics (47 centers), prospective data collection, near complete follow-up (.98%), and inclusion of a relatively high proportion of adolescents and patients with severe liver disease.The authors stratified the population into 3 subgroups according to whether treatment was continuous, discontinued, or intermittent, and intermittent was defined as successful resumption after temporary discontinuation.The increase in FEV 1 , body mass index, and reduction in pulmonary exacerbations mirrored the pivotal trial results in the overall population while adding granularity to the heterogeneity of clinical response.About 20% of the overall population had a 10% or greater increase in FEV 1 , whereas patients who discontinued treatment had a fall in FEV 1 and body mass index, and no reduction in pulmonary exacerbations.Interestingly, adolescents demonstrated a steady FEV 1 rise over the course of 1 year, and an overall greater increase compared with adults, who had a peak effect after 1 month of
P1.09-15 Hybrid Organoid Reveals That Podoplanin-Positive Cancer-Associated Fibroblasts Enhance Proliferation of Lung Cancer Cell
Authors: H. Nakamura, M. Sugano, T. Miyashita, H. Hashimoto, A. Ochiai, K. Suzuki, M. Tsuboi, G. Ishii
Journal: Journal of Thoracic Oncology (2019)
P1.01-108 PACIFIC-6: A Phase II Study of Durvalumab Following Sequential Chemoradiotherapy in Patients with Stage III, Unresectable NSCLC
Authors: M. Garassino, C. Faivre-Finn, J. Mazieres, M. Reck, U. Emeribe, A. Franks, N. Trunova
Journal: Journal of Thoracic Oncology (2019)
P2.04-79 High Rate of Immune Related Pneumonitis in Lung Cancer Patients Treated with Anti PD-1 Antibodies
Authors: A. Aguilar Hernandez, J.J. Garcia Mosquera, S. Viteri, M.J. Araujo, J. Bracht, C. Cambray, E. Belmonte, F. Coll-Klein, F. Cecere, M.A. Molina-Vila, F. Tresserra, M. Gonzalez-Cao, R. Rosell
Journal: Journal of Thoracic Oncology (2019)
Hematopoietic Stem Cells: Soluble Signals and Remodeling in a Synthetic Gelatin‐Based Hematopoietic Stem Cell Niche (Adv. Healthcare Mater. 20/2019)
Authors: Aidan E. Gilchrist, Sunho Lee, Yuhang Hu, Brendan A. C. Harley
Journal: Advanced Healthcare Materials (2019)

In article number 1900751 by Brendan A. C. Harley and co-workers, a library of gelatin hydrogels with well-defined biophysical and biotransport properties are used as an artificial hematopoietic stem cell (HSC) niche. This work explores the role of matrix remodeling and paracrine signals generated by co-cultured mesenchymal stem cells on HSC proliferation and quiescence.
EP1.01-14 The Scour Using Pretreatment NLR, Liver Metastasis, PD-L1 Status and PS as a Marker of Outcomes in Nivolumab-Treated Patients with Advanced NSCLC
Authors: A. Tamiya, M. Tamiya, Y. Taniguchi, K. Nakahama, S. Isa, T. Shiroyama, T. Inoue, H. Suzuki, K. Okishio, T. Hirashima, F. Imamura, S. Atagi
Journal: Journal of Thoracic Oncology (2019)
Abstract 16242: Anti-Inflammatory Therapy With Canakinumab and Reduction in Total Cardiovascular Events
Authors: Brendan M Everett, Jean G MacFadyen, Tom Thuren, Peter Libby, Robert J Glynn, Paul Ridker
Journal: Circulation (2018)

Introduction: Inflammation reduction with the interleukin (IL)-1β inhibitor canakinumab significantly reduces the first major adverse cardiovascular event in patients with prior myocardial infarcti...
P1.09-32 Concurrent Genomic Alterations in ALK-Rearranged Non-Small Cell Lung Cancer Patients
Authors: S. Clavé, M. Salido, J. Gibert, M. Hardy-Werbin, E. Weingartner, J. Hernandez, D. Nichol, P. Rocha, X. Riera, R. Blanco, J. Bosch-Barrera, Á. Taus, L. Pijuan, B. Bellosillo, E. Arriola
Journal: Journal of Thoracic Oncology (2019)
P2.12-21 Outcomes with Immune Checkpoint Inhibitors (ICI) for Relapsed Small Cell Lung Cancer (SCLC) in a Swiss Cohort
Authors: L. Mauti, S. Schmid, I. Demmer, A. Friedlaender, V. Blum, S. Rothschild, H. Bouchaab, P. Froesch, C. Britschgi, D. Koenig, L. Wannesson, W. Janthur, S. Schaer, A. Addeo, W. Jochum, M. Früh
Journal: Journal of Thoracic Oncology (2019)
Gender Disparities in Invited Commentary Authorship in 2459 Medical Journals
Authors: Emma G. Thomas, Bamini Jayabalasingham, Tom Collins, Jeroen Geertzen, Chinh Bui, Francesca Dominici
Journal: JAMA Network Open (2019)

In peer-reviewed medical journals, authoring an invited commentary on an original article is a recognition of expertise. It has been documented that women author fewer invited publications than men do. However, it is unknown whether this disparity is due to gender differences in characteristics that are associated with invitations, such as field of expertise, seniority, and scientific output.To estimate the odds ratio (OR) of authoring an invited commentary for women compared with men who had similar expertise, seniority, and publication metrics.This matched case-control study included all medical invited commentaries published from January 1, 2013, through December 31, 2017, in English-language medical journals and multidisciplinary journals. Invited commentaries were defined as publications that cite another publication within the same journal volume and issue. Bibliometric data were obtained from Scopus. Cases were defined as corresponding authors of invited commentaries in a given journal during the study period. Controls were matched to cases based on scientific expertise by calculating a similarity index for abstracts published during the same period using natural language processing. Data analyses were conducted from March 13, 2019, through May 3, 2019.Corresponding or sole author gender was predicted from author first name and country of origin using genderize.io.The OR for gender was estimated after adjusting for field of expertise, publication output, citation impact, and years active (ie, years since first publication), with an interaction between gender and years active.The final data set included 43 235 cases across 2549 journals; there were 34 047 unique intraciting commentary authors, among whom 9072 (26.6%) were women. For researchers who had been active for the median of 19 years, the odds of invited commentary authorship were 21% lower for women (OR, 0.79 [95% CI, 0.77-0.81]; P < .001) compared with men who had similar scientific expertise, number of publications, and citation impact. For every decile increase in years active, the OR decreased by a factor of 0.97 (95% CI, 0.96-0.98; P < .001).In this case-control study, women had lower odds of authoring invited commentaries than their male peers. This disparity was larger for senior researchers. Journal editors could use natural language processing of published research to widen and diversify the pool of experts considered for commentary invitations.
P1.04-34 Efficacy and Safety of First-Line Pembrolizumab Monotherapy in Elderly Patients (Aged ≥ 75 years) with Non-Small Cell Lung Cancer
Authors: T. Sugiyama, H. Imai, S. Wasamoto, O. Yamaguchi, K. Suzuki, J. Uchino, H. Minemura, T. Osaki, T. Ishii, Y. Umeda, H. Taniguchi, T. Kasai, K. Minato, K. Kaira
Journal: Journal of Thoracic Oncology (2019)
P1.18-03 How to Predict High Grade Radiation Pneumonitis in Non-Small Cell Lung Cancer Patients Treated with Thoracic Radiotherapy
Authors: J. Bordas-Martinez, C. Martin-Cabeza, S. Padrones-Sánchez, R. Palmero Sánchez, E. Nadal, V. Navarro-Párez, J. Dorca-Sargatal, A. Navarro-Martín, S. Aso-González
Journal: Journal of Thoracic Oncology (2019)
EP1.05-07 Examining Endobronchial Ultrasound (EBUS) Utilisation in Lung Cancer Diagnosis and Treatment Delay. A Restrospective Observational Study
Authors: R. Stirling, S.W. Khung, M. Hew, E. Dabscheck, D. Keating, T. Williams
Journal: Journal of Thoracic Oncology (2019)
P2.12-07 Phase I Study of Amrubicin and Cisplatin with Concurrent Thoracic Radiotherapy (TRT) in Limited-Disease Small Cell Lung Cancer (LD-SCLC)
Authors: M. Fukuda, M. Shimada, H. Yamaguchi, T. Kitazaki, D. Ogawara, K. Nakatomi, Y. Nakamura, T. Yamazaki, N. Hayashi, H. Mukae
Journal: Journal of Thoracic Oncology (2019)
P1.01-32 Bronchoalveolar Lavage as an Alternative to Rebiopsy for Detection of T790M Mutation in NSCLC Patients with Acquired Resistance to EGFR-TKIs
Authors: H. Kim, J.Y. Hur, I.A. Kim, S. Lee, W.S. Kim, K.Y. Lee
Journal: Journal of Thoracic Oncology (2019)
EP1.18-13 Review of Preoperative Examination
Authors: F. Hoshi, A. Sakurada, M. Noda, T. Sado, Y. Matsuda, H. Oishi, H. Notsuda, T. Hirama, S. Eba, H. Yabuki, M. Katahira, Y. Suzuki, K. Abe, K. Sato, H. Katsumata, H. Oshio, T. Yamada, Y. Okada
Journal: Journal of Thoracic Oncology (2019)
P2.01-64 Systemic Inflammatory Markers as a Predictors of Response to Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer
Authors: A. Bilici, O.F. Olmez, P. Gursoy, E. Çubukçu, O. Yildiz, A. Sakin, T. Korkmaz, I. Cil, B. Cakar, S. Menekse, T. Demir, O. Acikgoz, J. Hamdard
Journal: Journal of Thoracic Oncology (2019)
JCSE01.17 Modelling the Immunosuppressive Difference of SBRT and CRT by Simulating the Dose to Circulating Lymphocytes in Non-Small Cell Lung Cancer
Authors: Y. Shen, Y. Meng, X. Tang, P. Gu, C. Yu, W. Wang, F. Kong, H. Yang
Journal: Journal of Thoracic Oncology (2019)
P1.01-103 Preliminary Results of Brigatinib in Japanese Patients (Pts) Who Previously Received Alectinib: Brigatinib-2001 Study
Authors: S. Murakami, T. Seto, M. Satouchi, M. Nishio, H. Hayashi, Y. Ohe, T. Asato, P. Zhang, K. Nakagawa
Journal: Journal of Thoracic Oncology (2019)
Computed tomography assessment of peripheral traction bronchiolectasis: impact of minimal intensity projection
Authors: Constance de Margerie-Mellon, Lisa Belin, Samia Boussouar, Philippe Khafagy, Marie-Pierre Debray, Kim Levand, Marie-Laure Chabi, Antoine Khalil, Amira Benattia, Dominique Israël-Biet, Bruno Crestani, Hilario Nunes, Jacques Cadranel, Philippe Grenier, Dominique Valeyre, Jean-Marc Naccache, Pierre-Yves Brillet
Journal: European Respiratory Journal (2019)

<b>On chest CT, post-processing with minimal intensity projection does not improve inter-reader agreement for the identification of peripheral traction bronchiolectasis and honeycombing in patients with suspected idiopathic interstitial pneumonia.</b>http://bit.ly/35p8NlQ
P1.12-05 Microenvironment Characterization of Small Cell Lung Cancer Xenografts Implanted in Hematopoietic Humanized Mice
Authors: H. Yu, J. Lang, J. Kern, S. Lueke Pickard, C. Rudin, C. Rivard, F.R. Hirsch
Journal: Journal of Thoracic Oncology (2019)
OA08.03 A Single-Cell Resolution Map of EMT and Drug Resistance States for Evaluating NSCLC Clinical Specimens
Authors: L. Karacosta, B. Anchang, N. Ignatiadis, S. Kimmey, J. Benson, J. Shrager, A. Sung, J. Neal, H. Wakelee, R. Tibshirani, S. Bendall, S. Plevritis
Journal: Journal of Thoracic Oncology (2019)
Physician and Trainee Experiences With Patient Bias
Authors: Margaret Wheeler, Shalila de Bourmont, Kimani Paul-Emile, Alana Pfeffinger, Ashley McMullen, Jeff M. Critchfield, Alicia Fernandez
Journal: JAMA Internal Medicine (2019)

<h3>Importance</h3> As the clinical workforce becomes more diverse, physicians encounter patients who demean them based on social characteristics. Little is known about physicians' perspectives on these encounters and their effects. This knowledge would help develop policies and best practices for institutions and training programs. <h3>Objective</h3> To describe the range and importance of encounters with biased patients and the barriers and facilitators to effective responses. <h3>Design, Setting, and Participants</h3> This qualitative study recruited convenience samples of hospitalist attending physicians, internal medicine residents, and medical students from 3 campuses affiliated with 1 academic medical center. Data were collected from 50 individuals within 13 focus groups from May 9 through October 15, 2018. Focus groups were conducted using open-ended probes, audiotaped, and transcribed. Participants used their own definition of biased patient behavior. Each transcript was independently coded by at least 2 investigators. Data were analyzed from May 2018 through February 2019. <h3>Main Outcomes and Measures</h3> Major themes associated with types of encounter, importance to the participant, and barriers and facilitators to effective responses were abstracted through the constant comparative approach. <h3>Results</h3> Overall, 50 individuals (11 hospitalists, 26 residents, and 13 students) participated; 24 (48%) were nonwhite. At total of 26 participants (52%) identified as women; 22 (44%), as men; and 2 (4%), as gender nonconforming. Reports of biased behavior ranged from patient refusal of care and explicit racist, sexist, or homophobic remarks to belittling compliments or jokes. Targeted physicians reported an emotional toll that included exhaustion, self-doubt, and cynicism. Nontargeted bystanders reported moral distress and uncertainty about how to respond. Participant responses ranged from withdrawal from clinical role to a heightened determination to provide standard of care. Barriers to effective responses included lack of skills, insufficient support from senior colleagues and the institution, and perception of lack of utility associated with responding. Participants expressed a need for training on dealing with biased patients and for clear institutional policies to guide responses. <h3>Conclusions and Relevance</h3> In this qualitative study of physicians and medical students, encounters with demeaning patients ranged from refusal of care to belittling jokes and were highly challenging and painful. Addressing biased patient behavior will require a concerted effort from medical schools and hospitals to create policies and trainings conducive to a clinical environment that respects the diversity of patients and physicians alike.
Follistatin-like Protein 1 Inhibits Lung Cancer Metastasis by Preventing Proteolytic Activation of Osteopontin
Authors: Jean Chiou, Yu-Chan Chang, Hsing-Fang Tsai, Yuan-Feng Lin, Ming-Shyan Huang, Chih-Jen Yang, Michael Hsiao
Journal: Cancer Research (2019)

Follistatin-like protein 1 (FSTL1) plays a critical role in lung organogenesis, but is downregulated during lung cancer development and progression. The prognostic significance and functional consequences of FSTL1 downregulation in lung cancer are unclear. Here, reduced levels of FSTL1 were detected in various tumors compared with normal tissues and were associated with poor clinical outcome in patients with non-small cell lung cancer, particularly those with lung adenocarcinoma. FSTL1 expression negatively correlated with the metastatic potential of lung cancer cells. Antibody-based neutralization of extracellular FSTL1 increased cellular migration/invasion while addition of recombinant FSTL1 protein diminished the metastatic capacity of lung cancer cells in vitro and in vivo. Notably, treatment with FSTL1 effectively prevented the metastatic progression of lung cancer cells in an orthotopic animal model. Mechanistically, FSTL1 directly bound to the proform of secreted phosphoprotein 1 (SPP1)/osteopontin, restraining proteolytic activation of SPP1, which led to inactivation of integrin/CD44-associated signaling and rearrangement of the actin cytoskeleton. Combined low expression of FSTL1 and high expression of SPP1 predicted a poorer prognosis for patients with lung cancer. This study highlights the novel interaction between FSTL1 and SPP1 and new opportunities to effectively target SPP1-driven metastatic cancers characterized by FSTL1 downregulation. SIGNIFICANCE: These findings describe the novel interaction between FSTL1 and SPP1 and its role in the metastatic progression of lung adenocarcinoma.
Association of Disposable Perioperative Jackets With Surgical Site Infections in a Large Multicenter Health Care Organization
Authors: Erik J. Stapleton, Nicholas Frane, Jonathon M. Lentz, Donna Armellino, Nina Kohn, Rosemarie Linton, Adam D. Bitterman
Journal: JAMA Surgery (2019)

<h3>Importance</h3> To help prevent surgical site infections (SSIs), recommendations by a national organization led to implementation of a mandatory operating room policy in a large multicenter health care organization of required use of disposable perioperative jackets. <h3>Objective</h3> To assess whether the use of perioperative disposable jackets is associated with the incidence of SSIs. <h3>Design, Setting, and Participants</h3> Surgical site infection data for patients undergoing clean surgical procedures were retrospectively reviewed from 12 hospitals in a large multicenter health care organization during a 55-month period from January 1, 2014, to July 31, 2018. The incidence of SSI was analyzed for all National Healthcare Safety Network monitored and reported procedures. The patient population was split into 2 groups; the preintervention group consisted of 29 098 patients within the 26 months before the policy starting March 1, 2016, and the postintervention group consisted of 30 911 patients within 26 months after the policy. <h3>Main Outcome and Measures</h3> Comparison of the incidence of SSIs before and after intervention periods underwent statistical analysis. The total number of disposable jackets purchased and total expenditures were also calculated. <h3>Exposures</h3> Implementation of the mandated perioperative attire policy. <h3>Results</h3> A total of 60 009 patients (mean [SD] age, 62.8 [13.9] years; 32 139 [53.6%] male) were included in the study. The overall SSI incidence for clean wounds was 0.87% before policy implementation and 0.83% after policy implementation, which was not found to be significant (odds ratio [OR], 0.96; 95% CI, 0.80-1.14;<i>P</i> = .61). After accounting for possible confounding variables, a multivariable analysis demonstrated no significant reduction in SSIs (OR, 0.85; 95% CI, 0.71-1.01;<i>P</i> = .07). During the postintervention study period (26 months), a total of 2 010 040 jackets were purchased, which amounted to a cost of $1 709 898.46. <h3>Conclusions and Relevance</h3> The results of this study suggest that the use of perioperative disposable jackets is not associated with reductions in SSI for clean wounds in a large multicenter health care organization and presents a fiscal burden.
Absolute and Relative Blood Lymphocyte Subset Counts before and during Treatment of Patients with Thrombotic Thrombocytopenic Purpura (TTP).
Authors: Ulla A. Axdorph, Maha Elias, Mona Hansson, Johanna A. Kremer Hovinga, Bernhard Lammle, Magnus Bjorkholm
Journal: Blood (2006)
P2.09-22 Molecular and Immunological Profiles of Lung Carcinoma: Are They Associated?
Authors: A. Cruz, I. Guerreiro, M.J. Silva, M.J. Leitão, A. Rodrigues, I. Azevedo, I. Pousa, J. Oliveira, C. Oliveira, A. Rosinha, M. Cassiano, A.L. Cunha, M. Soares
Journal: Journal of Thoracic Oncology (2019)
MA17.09 5-Azacytidine Inhaled Dry Powder Formulation Profoundly Improves Pharmacokinetics and Efficacy for Lung Cancer Therapy
Authors: P. Kuehl, C. Tellez, M. Grimes, M. Burke, A. Badenoch, D. Dubose, S. Belinsky
Journal: Journal of Thoracic Oncology (2019)
P2.13-12 Endobronchial Ultrasound for Diagnosis and Staging of Lung Cancer: Our Experience
Authors: A. De Palma, G. Garofalo, E. Maiolino, T. Panza, F. Signore, A. Fiorella, O. Pizzuto, X. Trabucco, G. Marulli
Journal: Journal of Thoracic Oncology (2019)
The Distinguished Legacy of Linda S. Birnbaum, an Environmental Health Champion
Authors: Richard K. Kwok, Brian R. Berridge, John R. Bucher, Gwen W. Collman, Janet E. Hall, Mary E. Jacobson, W. Chris Long, Aubrey K. Miller, Mark F. Miller, Rick P. Woychik, Darryl C. Zeldin
Journal: Environmental Health Perspectives (2019)
Putting health equity at heart of universal coverage—the need for national programmes of action
Authors: Eric A Friedman, Lawrence O Gostin, Matthew M Kavanagh, Mirta Roses Periago, Michael Marmot, Anna Coates, Agnes Binagwaho, Joia Mukherjee, Mushtaque Chowdhury, Tracy Robinson, Valdiléa G Veloso, Chenguang Wang, Miriam Were
Journal: BMJ (2019)

and colleagues
EP1.14-09 Characterization of Actionable BRAFV600E and Co-Mutations in Non-Small Cell Lung Cancer (NSCLC) Patients
Authors: P. Sanvarinda, S. Oranratnachai, S. Detarkom, N. Iemwimangsa, N. Trachu, P. Incharoen, W. Chantratita, T. Reungwetwattana
Journal: Journal of Thoracic Oncology (2019)
OA08.07 Aberrant Epigenetic SMAD3 Signaling in Tumor-Associated Fibroblasts Modulates Fibrosis and Response to Nintedanib in NSCLC
Authors: R. Ikemori, M. Gabasa, M. Vizoso, P. Duch, S. Moran, S. Gea-Sorli, P. Bragado, T. Jauset, M. Esteller, L. Soucek, E. Monsó, V. Peinado, C. Fillat, F. Hilberg, N. Reguart, J. Alcaraz
Journal: Journal of Thoracic Oncology (2019)
EP1.16-29 Clinical Characteristics and Outcomes of Postoperative Empyema Following Lung Surgery
Authors: K. Kameyama, S. Okada, M. Shimomura, H. Tsunezuka, S. Ishihara, S. Ikebe, T. Furuya, N. Ishikawa, S. Kitaoka, J. Shimada, M. Inoue
Journal: Journal of Thoracic Oncology (2019)
P1.09-21 Tumor Responses Based on Tumor Growth Rate During PD-1 Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients
Authors: D. Ten Berge, D. Hurkmans, I. Den Besten, J. Kloover, R. Mathijssen, R. Debets, J. Aerts, E. Smit
Journal: Journal of Thoracic Oncology (2019)